Akèy › Kansè Ezofajyen › Kalifòni › Los Angeles
Etid klinik pou Kansè Ezofajyen nan Los Angeles, CA
15 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Ap rekriteFaz 1/2
- UCLA Hematology/Oncology - Santa Monica ( Site 4905), Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Ap rekriteFaz 3
- UCLA, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Ap rekriteFaz 1/2
- UCLA Hematology/Oncology - Santa Monica ( Site 8905), Los Angeles
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Ap rekriteFaz 1/2
- UCLA Hematology/Oncology - Santa Monica ( Site 6905), Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Oncology Institute for Hope and Innovation, Los Angeles
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Ap rekrite
- Cedars-Sinai Medical Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Ap rekriteFaz 4
- Cedars-Sinai Medical Center, Los Angeles
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UCLA Medical Center, Los Angeles
Etid Kansè Ezofajyen nan lòt vil
- Houston, TX36 etid
- Boston, MA23 etid
- New York City, NY22 etid
- Nashville, TN19 etid
- St. Louis, MO17 etid
- Pittsburgh, PA15 etid
- Baldwin Park, CA14 etid
- Grand Rapids, MI14 etid
- Philadelphia, PA13 etid
- San Antonio, TX12 etid
- Dallas, TX11 etid
- Arlington, VA11 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.